<p><strong>Cardio Diagnostics Holdings Inc.</strong> (NASDAQ: CDIO) 周四宣布了一项 重大国际合作。</p>
<p>Cardio Diagnostics、<strong>Aimil Ltd.</strong> 和 <strong>Dr. Lal PathLabs Ltd</strong>. 揭示了一项将 PrecisionCHD 冠状动脉测试引入印度的协议。</p>
<p>此次合作标志着 Cardio Diagnostics 首次在美国以外扩展，目标是一个心脏病发病率上升的国家。</p>
<p>该测试结合了表观遗传学、遗传学和人工智能，从血样中检测分子水平的冠状动脉心脏病。</p>
<h2><strong>临床优势</strong></h2>
<p>PrecisionCHD 能够识别传统血管造影通常漏掉的阻塞性和非阻塞性冠状动脉心脏病形式。</p>
<p>印度的冠状动脉心脏病发病率在某些城市人群中高达 13%，凸显了紧急筛查的需求。</p>
<p>合作伙伴已开始将该测试整合到 Dr. Lal PathLabs 的临床和实验室网络中，遵循印度的临床指南。</p>
<p>在整合和监管对接后，该集团预计将在 2026 年实现更广泛的商业部署。</p>
<h2><strong>高管见解</strong></h2>
<p>Cardio Diagnostics 首席执行官兼联合创始人 <strong>Dr. Meesha Dogan</strong> 表示，此次合作促进了对尖端心血管护理的公平获取。</p>
<p>Aimil 执行董事 <strong>Dr. Mallika Kapur</strong> 表示，该项目加强了印度对先进心脏诊断的获取。</p>
<p>Dr. Lal PathLabs 首席执行官 <strong>Shankha Banerjee</strong> 表示，该测试将帮助临床医生更早地发现疾病并量身定制治疗方案。</p>
<p><strong>CDIO 股价动态：</strong> Cardio Diagnostics 的股票在周四发布时下跌 15.77%，报 $2.35。该股票交易于新的 52 周低点，根据 Benzinga Pro 数据。</p>
<p><em>图片来源于 Shutterstock</em></p>

CDIO

<p>Cardio Diagnostics 已与 Aimil Ltd.和 Dr. Lal PathLabs 合作，在印度推出 PrecisionCHD 测试，旨在应对该国高发的心脏病率。这标志着 Cardio Diagnostics 首次国际扩张，利用人工智能和表观遗传学从血液样本中检测冠心病。该测试旨在改善早期检测和治疗个性化。与 Dr. Lal PathLabs 网络的整合正在进行中，预计将在 2026 年实现更广泛的部署。Cardio Diagnostics 的股价下跌 15.77%，至 2.35 美元，创下 52 周新低</p>

<p><strong>Cardio Diagnostics Holdings Inc.</strong> (NASDAQ: CDIO) announced a major international partnership on Thursday.</p>
<div class="lb-trans"><p><strong>Cardio Diagnostics Holdings Inc.</strong> (NASDAQ: CDIO) 周四宣布了一项 重大国际合作。</p>
</div><p>Cardio Diagnostics, <strong>Aimil Ltd.</strong> and <strong>Dr. Lal PathLabs Ltd</strong>. revealed a deal to bring the PrecisionCHD coronary test to India.</p>
<div class="lb-trans"><p>Cardio Diagnostics、<strong>Aimil Ltd.</strong> 和 <strong>Dr. Lal PathLabs Ltd</strong>. 揭示了一项将 PrecisionCHD 冠状动脉测试引入印度的协议。</p>
</div><p>The collaboration marks Cardio Diagnostics' first expansion outside the United States, targeting a nation with rising heart disease rates.</p>
<div class="lb-trans"><p>此次合作标志着 Cardio Diagnostics 首次在美国以外扩展，目标是一个心脏病发病率上升的国家。</p>
</div><p>The test combines epigenetics, genetics and AI to detect coronary heart disease at a molecular level from a blood sample.</p>
<div class="lb-trans"><p>该测试结合了表观遗传学、遗传学和人工智能，从血样中检测分子水平的冠状动脉心脏病。</p>
</div><h2><strong>Clinical Advantage</strong></h2>
<div class="lb-trans"><h2><strong>临床优势</strong></h2>
</div><p>PrecisionCHD can identify both obstructive and non-obstructive CHD forms usually missed by traditional angiograms.</p>
<div class="lb-trans"><p>PrecisionCHD 能够识别传统血管造影通常漏掉的阻塞性和非阻塞性冠状动脉心脏病形式。</p>
</div><p>Coronary heart disease rates in India range as high as 13% in some urban populations, underscoring urgent screening demand.</p>
<div class="lb-trans"><p>印度的冠状动脉心脏病发病率在某些城市人群中高达 13%，凸显了紧急筛查的需求。</p>
</div><p>Partners have started integrating the test into Dr. Lal PathLabs' clinical and lab network under Indian clinical guidelines.</p>
<div class="lb-trans"><p>合作伙伴已开始将该测试整合到 Dr. Lal PathLabs 的临床和实验室网络中，遵循印度的临床指南。</p>
</div><p>After integration and regulatory alignment, the group expects broader commercial deployment in 2026.</p>
<div class="lb-trans"><p>在整合和监管对接后，该集团预计将在 2026 年实现更广泛的商业部署。</p>
</div><h2><strong>Executive Insight</strong></h2>
<div class="lb-trans"><h2><strong>高管见解</strong></h2>
</div><p>Cardio Diagnostics CEO and co-founder <strong>Dr. Meesha Dogan</strong> said the tie-up advances equitable access to cutting-edge cardiovascular care.</p>
<div class="lb-trans"><p>Cardio Diagnostics 首席执行官兼联合创始人 <strong>Dr. Meesha Dogan</strong> 表示，此次合作促进了对尖端心血管护理的公平获取。</p>
</div><p>Aimil Executive Director <strong>Dr. Mallika Kapur</strong> said the venture strengthens India's access to advanced heart diagnostics.</p>
<div class="lb-trans"><p>Aimil 执行董事 <strong>Dr. Mallika Kapur</strong> 表示，该项目加强了印度对先进心脏诊断的获取。</p>
</div><p>Dr. Lal PathLabs CEO <strong>Shankha Banerjee</strong> said the test will help clinicians detect disease earlier and tailor treatments.</p>
<div class="lb-trans"><p>Dr. Lal PathLabs 首席执行官 <strong>Shankha Banerjee</strong> 表示，该测试将帮助临床医生更早地发现疾病并量身定制治疗方案。</p>
</div><p><strong>CDIO Price Action:</strong> Cardio Diagnostics shares were down 15.77% at $2.35 at the time of publication on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>CDIO 股价动态：</strong> Cardio Diagnostics 的股票在周四发布时下跌 15.77%，报 $2.35。该股票交易于新的 52 周低点，根据 Benzinga Pro 数据。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

Cardio Diagnostics 寄希望于印度以扩大其 AI 心脏诊断业务